New All-Oral Combo Set to Transform Elderly AML Care

Older patients with newly diagnosed acute myeloid leukemia (AML) frequently cannot undergo intensive chemotherapy. Consequently, they require alternative therapeutic regimens that offer both efficacy and convenience. Recently, researchers evaluated a promising oral AML treatment in the clinical setting. This study investigated oral decitabine-cedazuridine combined with venetoclax. Crucially, this combination aims to replace traditional intravenous regimens.

Evaluating the Oral AML Treatment Combo

The Phase 1-2 ASCERTAIN-V trial enrolled 189 patients. These patients were either 75 years or older or ineligible for intensive chemotherapy. Specifically, the participants received oral decitabine-cedazuridine alongside oral venetoclax. To manage bone marrow suppression, investigators adjusted the treatment schedule during the trial. Furthermore, the trial primarily measured safety, drug interactions, and complete response rates. Ultimately, the results demonstrated no major drug-drug interactions between the two oral agents.

Efficacy and Survival Outcomes

The study showed remarkable efficacy outcomes. Indeed, the complete response rate in the pivotal Phase 2b cohort was 47 percent. Additionally, the rate of complete response with incomplete hematologic recovery reached 63 percent. Therefore, a significant majority of patients experienced clinical benefit. Moreover, the median overall survival of the participants was 15.5 months. This survival duration is highly comparable to traditional intravenous therapies. However, clinicians must still monitor patients closely for treatment-related side effects.

Adverse Events and Patient Tolerability

Like other leukemia therapies, this regimen can cause myelosuppressive side effects. For instance, the most common grade 3 or higher adverse events included anemia and neutropenia. Specifically, anemia affected 30 percent of the study participants. Meanwhile, 26 percent of the patients experienced neutropenia, and 25 percent developed febrile neutropenia. Fortunately, the 30-day mortality rate was low at only 3 percent. As a result, this treatment presents a manageable safety profile for fragile elderly patients.

Frequently Asked Questions

Q1: What are the main benefits of this new oral AML treatment?

The combination eliminates the need for frequent hospital visits for intravenous chemotherapy. Thus, it reduces the patient burden while maintaining high efficacy rates.

Q2: What was the complete response rate in the ASCERTAIN-V trial?

In the Phase 2b cohort, 47 percent of the patients achieved a complete response. Additionally, 63 percent achieved a complete response or complete response with incomplete hematologic recovery.

Q3: What were the most common severe adverse events?

The most common grade 3 or higher adverse events were anemia, neutropenia, and febrile neutropenia. However, early mortality rates remained low during the clinical trial.

References

1. Roboz GJ et al. All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia. N Engl J Med. 2026 Jun 04. doi: 10.1056/NEJMoa2510223. PMID: 42235013.
2. U.S. Food and Drug Administration (FDA). FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia. May 13, 2026.
3. Taiho Oncology, Inc. Taiho Oncology Announces New England Journal of Medicine Publication of First All-Oral Regimen in Newly Diagnosed Acute Myeloid Leukemia. June 3, 2026.